Advertisement


Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial

2017 Gastrointestinal Cancers Symposium

Advertisement

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).



Related Videos

Colorectal Cancer

Brendan J. Guercio, MD, on Colorectal Cancer and Physical Activity: Impact on Survival

Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).

Colorectal Cancer

Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).

Gastroesophageal Cancer

Karyn A. Goodman, MD, on Esophageal Cancer: Results of CALGB 80803

Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).

Hepatobiliary Cancer

Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial (Spanish Language Version)

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).

Colorectal Cancer

Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).

Advertisement

Advertisement




Advertisement